Please login to the form below

Not currently logged in
Email:
Password:

Teva/Cephalon deal faces delay

Teva and Cephalon have been asked to provide additional information regarding the proposed takeover

Teva Pharmaceutical Industries and Cephalon have received a request for additional information from the US Federal Trade Commission (FTC) in connection with Teva's $6.8bn pending acquisition of Cephalon. The request will extend the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period until 30 days after the parties have substantially complied with the request, unless that period is terminated sooner by the FTC.

The companies said that they have been cooperating with FTC staff since shortly after the announcement of the transaction and intend to continue to cooperate with the FTC to obtain clearance as promptly as possible.

The companies said they expect that the takeover to be completed in the third quarter of 2011, following completion of the HSR clearance process, clearance by the European Commission under the EC Merger Regulation, and the approval of Cephalon stockholders.Meanwhile Teva has signed a $4bn credit deal with a banking syndicate, made up of European, US, Canadian and Israeli banks.

15th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...